- Home
- ROIV vs MASI Comparison
ROIV vs MASI Comparison
Compare ROIV & MASI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ROIV
- MASI
- Stock Information
- Founded
- ROIV 2014
- MASI 1989
- Country
- ROIV United Kingdom
- MASI United States
- Employees
- ROIV N/A
- MASI N/A
- Industry
- ROIV Biotechnology: Pharmaceutical Preparations
- MASI Medical/Dental Instruments
- Sector
- ROIV Health Care
- MASI Health Care
- Exchange
- ROIV Nasdaq
- MASI Nasdaq
- Market Cap
- ROIV 7.8B
- MASI 8.2B
- IPO Year
- ROIV N/A
- MASI 2007
- Fundamental
- Price
- ROIV $10.99
- MASI $167.57
- Analyst Decision
- ROIV Buy
- MASI Buy
- Analyst Count
- ROIV 4
- MASI 6
- Target Price
- ROIV $17.50
- MASI $187.00
- AVG Volume (30 Days)
- ROIV 7.3M
- MASI 612.2K
- Earning Date
- ROIV 08-07-2025
- MASI 08-05-2025
- Dividend Yield
- ROIV N/A
- MASI N/A
- EPS Growth
- ROIV N/A
- MASI N/A
- EPS
- ROIV N/A
- MASI N/A
- Revenue
- ROIV $29,053,000.00
- MASI $2,126,800,000.00
- Revenue This Year
- ROIV $2.64
- MASI N/A
- Revenue Next Year
- ROIV $378.09
- MASI $7.74
- P/E Ratio
- ROIV N/A
- MASI N/A
- Revenue Growth
- ROIV N/A
- MASI 16.68
- 52 Week Low
- ROIV $8.73
- MASI $101.61
- 52 Week High
- ROIV $13.06
- MASI $194.88
- Technical
- Relative Strength Index (RSI)
- ROIV 44.75
- MASI 53.62
- Support Level
- ROIV $10.83
- MASI $163.29
- Resistance Level
- ROIV $11.82
- MASI $172.55
- Average True Range (ATR)
- ROIV 0.32
- MASI 4.92
- MACD
- ROIV -0.07
- MASI 0.09
- Stochastic Oscillator
- ROIV 16.24
- MASI 60.97
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
About MASI Masimo Corporation
Masimo Corp is a global technology company. The company's segment includes healthcare and non-healthcare. The healthcare business segment is a key revenue driver, develops, manufactures, and markets a variety of noninvasive patient monitoring technologies, hospital automation and connectivity solutions, remote monitoring devices and consumer health products. Its non-healthcare segment includes consumer audio business develops, manufactures, markets sells and licenses premium and luxury audio sound products and related integration technologies.